NEWS | SAN DIEGO

Analyst cuts Amylin rating on improved share price

By

An analyst downgraded shares of San Diego-based Amylin Pharmaceuticals Inc. (Nasdaq: AMLN) Thursday, noting that the diabetes drug maker's stock has surged in 2012.

TO CONTINUE READING, SUBSCRIBE NOW
OR
LOG IN TO YOUR ACCOUNT
User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

Amylin Pharmaceuticals Inc.

Company Website

9360 Towne Centre Dr., Suite 110
San Diego, CA 92121
Map It

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
AMLN
30.98
  -0.02  
- 0.06%
2,309,586,000
31.02
8.03

Insider Trade Data

Date Insider Shares Type Value
07/26/2012 Kolterman, Orville G 20,300 Exchange $242,585
07/26/2012 Bradbury, Daniel M 36,000 Exchange $430,200
05/11/2012 Skyler, Jay S 18,000 Exchange $167,280
03/29/2012 Rowland, Lloyd A 8,000 Sell $189,150
03/28/2012 Rowland, Lloyd A 5,000 Exchange $45,100

Amylin Pharmaceuticals Inc. Executive(s):

Ginger Graham

  • Chief Executive Officer

Daniel Bradbury

  • Chief Executive Officer, President

Howard Greene

Similar Companies

NAICS - 325411 - Medicinal and Botanical Manufacturing
SIC - 2833 - MEDICINAL CHEMICALS AND BOTANICAL PRODUCTS
NAICS - 541711 - Research and Development in Biotechnology
SIC - 8731 - COMMERCIAL PHYSICAL AND BIOLOGICAL RESEARCH
SIC - 8733 - NONCOMMERCIAL RESEARCH ORGANIZATIONS



Subscribe Today!

contact info: Iam Pam